Austin, TX – According to filings with the U.S. Securities and Exchange Commission, Shattuck Labs is raising $83,000,009.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Taylor Schreiber played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Shattuck Labs

Shattuck is developing a breakthrough platform for immunotherapy, which harnesses the human immune system to improve outcomes for patients battling cancer and inflammatory disease. Shattuck’s proprietary technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple, synergistic functions. Shattuck was founded to solve the challenge of consolidating checkpoint blockade and Tumor Necrosis Factor Receptor Superfamily (TNFRSF) agonism into single therapeutics. The Agonist Redirected Checkpoint (ARCÖ) platform has emerged as the first therapeutic modality to achieve this goal. Using the modularily of the ARC platform, Shattuck has created over 300 unique therapeutic candidates for the treatment of cancer and autoimmune disease.

To learn more about Shattuck Labs, visit http://www.shattucklabs.com/

Contact:
Taylor Schreiber, Chief Executive Officer
919-864-2700
tschreiber@shattucklabs.com
https://www.linkedin.com/in/taylor-schreiber-m-d-ph-d-28003b17/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved